Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28200881 | 0.87 | MAPT (0.45) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL9666274 | 0.86 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28200249 | 0.85 | MAPT (0.47) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL9663611 | 0.84 | ALDH1A1 (0.46) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL9665191 | 0.82 | MEN1 (0.49) | SLC6A4HTR2ASLC6A2SLC6A3CYP2D6 | |
| SCHEMBL9666074 | 0.81 | OPRM1 (0.49) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL9666286 | 0.80 | SMN1; SMN2 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL9463489 | 0.80 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CYP3A4OPRM1 | |
| SCHEMBL9664389 | 0.78 | SLC6A4 (0.72) | SLC6A4HTR2ASLC6A2SLC6A3 | |
| SCHEMBL24497314 | 0.74 | SLC6A4 (0.40) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-5028630-A | Benzylamines | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1991-07-02 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5162371-A | Benzylamine Devivatives | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1992-11-10 | — | — | US | disclosed |
| US-5028630-A | Benzylamines | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1991-07-02 | — | — | US | disclosed |
| US-4444778-A | ANTISEROTONINE AGENTS | COUGHLIN SHAUN R | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | SLC6A4 1081/4885HTR2A 2235/4885SLC6A2 999/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | SLC6A4 1369/4885HTR2A 2530/4885SLC6A2 361/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | SLC6A4 1081/4885HTR2A 2235/4885SLC6A2 999/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | SLC6A4 1369/4885HTR2A 2530/4885SLC6A2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.